Comprehensive Monograph on Celecoxib (DrugBank ID: DB00482)

Executive Summary

Celecoxib is a potent non-steroidal anti-inflammatory drug (NSAID) that represents a distinct therapeutic class as the only orally available selective cyclooxygenase-2 (COX-2) inhibitor in the United States. Its primary mechanism involves the targeted inhibition of the COX-2 enzyme, which is induced during inflammation, thereby reducing the synthesis of pain- and inflammation-mediating prostaglandins. This selectivity allows it to spare the constitutively expressed COX-1 enzyme, which is responsible for gastrointestinal (GI) mucosal protection and platelet function. Consequently, celecoxib offers comparable analgesic and anti-inflammatory efficacy to traditional non-selective NSAIDs like ibuprofen and naproxen, but with a significantly lower risk of GI ulceration and bleeding.

The drug is approved for a range of conditions, including osteoarthritis, rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, acute pain, primary dysmenorrhea, and, in an oral solution formulation, acute migraine. It also holds a unique indication for reducing adenomatous colorectal polyps in patients with familial adenomatous polyposis (FAP). Pharmacokinetically, celecoxib is characterized by rapid absorption, extensive tissue distribution, and a half-life of approximately 11 hours. Its metabolism is critically dependent on the cytochrome P450 isoenzyme CYP2C9, a pathway subject to significant genetic polymorphism and drug-drug interactions, necessitating careful dose consideration in poor metabolizers and with co-administration of CYP2C9 inhibitors.

The therapeutic profile of celecoxib is defined by a critical risk-benefit trade-off, encapsulated in its FDA-mandated boxed warnings. While offering superior GI safety, it carries an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke. Landmark clinical trials, notably the PRECISION study, have established that this cardiovascular risk is non-inferior to that of other common NSAIDs at moderate doses, reframing the discussion from a unique coxib-related danger to a class-wide NSAID risk. Therefore, the clinical application of celecoxib requires careful patient selection, prioritizing individuals at high GI risk while considering underlying cardiovascular health. Treatment should always adhere to the principle of using the lowest effective dose for the shortest possible duration.

Drug Identification and Chemical Profile

Celecoxib is a small molecule drug that belongs to a specific subclass of non-steroidal anti-inflammatory drugs (NSAIDs) distinguished by its selective mechanism of action.[1] As a well-established therapeutic agent, it is identified by a comprehensive set of chemical, regulatory, and commercial identifiers.

Nomenclature and Identifiers

The standard generic name for the compound is Celecoxib.[1] In accordance with international standards, it is also known by its International Nonproprietary Name (INN) variants, including

Célécoxib (French) and Celecoxibum (Latin).[1] Commercially, it was first marketed and is most widely known under the brand name Celebrex.[1] Other brand names include Elyxyb, an oral solution formulation, and the historical brand Onsenal, used for its indication in familial adenomatous polyposis.[1]

In scientific and regulatory databases, celecoxib is cataloged under several unique identifiers. Its DrugBank Accession Number is DB00482.[1] The Chemical Abstracts Service (CAS) has assigned it the registry number 169590-42-5.[6] During its development and in research literature, it has also been referred to by the codes SC-58635 and YM-177.[7] For regulatory purposes, its FDA Unique Ingredient Identifier (UNII) is JCX84Q7J1L.[8]

Chemical Structure and Formula

From a chemical standpoint, celecoxib is classified as a diaryl-substituted pyrazole, a structural characteristic that is fundamental to its pharmacological activity.[8] It is a member of the class of N-Substituted Monocyclic Pyrazoles and is also categorized as a sulfonamide due to the presence of a benzenesulfonamide group, a feature with implications for hypersensitivity reactions.[5]

The formal IUPAC (International Union of Pure and Applied Chemistry) name for the molecule is 4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide.[2] A common synonym is 5-(4-Methylphenyl)-1-(4-sulfamoylphenyl)-3-(trifluoromethyl)pyrazole.[7] Its empirical and molecular formula is

C17​H14​F3​N3​O2​S.[12] This corresponds to a molecular weight of approximately 381.37 g/mol.[7] The structure is uniquely defined by its Canonical SMILES (Simplified Molecular Input Line Entry System) string, CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F, and its InChIKey, RZEKVGVHFLEQIL-UHFFFAOYSA-N, which serves as a digital signature for the compound.[5]

Physicochemical Properties

Celecoxib presents as a white to almost white powder or crystalline powder and is a solid at room temperature (20°C).[7] A notable characteristic is its poor solubility in water, with a reported solubility of only 7 mg/L at 25°C.[8] This low aqueous solubility is a defining feature of its biopharmaceutical properties. In contrast, it is soluble in ethanol and freely soluble in methanol.[7] According to the Biopharmaceutics Classification System (BCS), celecoxib is a Class 2 drug, characterized by low solubility and high permeability.[8] This classification provides a scientific basis for several of its observed pharmacokinetic behaviors, such as the influence of food on its absorption and the non-linear increase in plasma concentrations at higher doses.[14]

The melting point of celecoxib is reported within a range of 157°C to 165°C across various sources.[7] This variability may be attributable to the existence of crystal polymorphism, a phenomenon where a solid compound can exist in more than one crystal form.[13] The compound is chemically stable, with a shelf life of at least four years when stored as a solid under appropriate conditions.[9]

Property	Value	Source(s)
Generic Name	Celecoxib	1
Brand Names	Celebrex, Elyxyb, Onsenal	1
DrugBank ID	DB00482	1
CAS Registry Number	169590-42-5	7
IUPAC Name	4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide	2
Molecular Formula	C17​H14​F3​N3​O2​S	12
Molecular Weight	381.37 g/mol	7
Chemical Class	Diaryl-substituted pyrazole, Sulfonamide	5
Appearance	White to almost white powder or crystal	7
Melting Point	161–165 °C	7
Water Solubility	Practically insoluble (7 mg/L at 25 °C)	8
Other Solubilities	Soluble in ethanol, freely soluble in methanol	13
BCS Class	Class 2 (Low Solubility, High Permeability)	8

Comprehensive Pharmacological Profile

The clinical utility and risk profile of celecoxib are direct consequences of its distinct pharmacological properties. Its pharmacodynamics explain its therapeutic effects and the basis for its improved gastrointestinal safety profile, while its pharmacokinetics dictate dosing, predict variability between patients, and form the basis for its significant drug-drug interactions.

Pharmacodynamics and Mechanism of Action

Primary Mechanism: Selective COX-2 Inhibition

Celecoxib is a non-steroidal anti-inflammatory drug (NSAID) whose therapeutic effects—analgesic, anti-inflammatory, and antipyretic—are derived from its selective inhibition of the cyclooxygenase-2 (COX-2) enzyme.[10] By blocking COX-2, celecoxib prevents the enzymatic conversion of arachidonic acid to prostaglandins, which are critical lipid mediators in the pathways of pain and inflammation.[10]

The fundamental therapeutic principle that distinguishes celecoxib from traditional NSAIDs like ibuprofen and naproxen is its selectivity.[7] The cyclooxygenase enzyme exists in two primary isoforms. COX-1 is a "housekeeping" or constitutive enzyme, continuously expressed in many tissues, where it synthesizes prostaglandins that perform vital physiological functions, most notably protecting the gastric mucosal lining and mediating platelet aggregation for hemostasis.[3] In contrast, the COX-2 isoform is primarily an inducible enzyme. Its expression is low in most resting tissues but is dramatically upregulated at sites of injury and inflammation by mediators such as cytokines.[1]

Traditional, non-selective NSAIDs inhibit both COX-1 and COX-2. While their inhibition of COX-2 produces the desired anti-inflammatory and analgesic effects, their concurrent inhibition of COX-1 disrupts its protective functions, leading to the class's most common and serious side effects: gastric irritation, peptic ulcers, and gastrointestinal bleeding.[8] The development of celecoxib was predicated on the hypothesis that selectively inhibiting the inflammation-induced COX-2 enzyme, while sparing the protective COX-1 enzyme at therapeutic concentrations, would uncouple the desired anti-inflammatory effects from the undesired GI toxicity.[7] Extensive clinical data have since validated this premise, demonstrating that celecoxib is associated with a significantly lower incidence of GI complications compared to its non-selective counterparts.[1]

Molecular Binding and Selectivity

Celecoxib's selectivity is a function of its unique chemical structure interacting with subtle differences between the active sites of the two COX isoforms. It acts as a selective, noncompetitive inhibitor of COX-2.[1] The key structural feature is its sulfonamide group, which is able to fit into a hydrophilic side pocket present within the active site of the COX-2 enzyme. This side pocket is absent in the COX-1 enzyme due to a single amino acid difference (isoleucine in COX-1 versus valine in COX-2), which sterically hinders the binding of celecoxib-like molecules.[8] This structural distinction is the molecular basis for the drug's selectivity.

The degree of this selectivity can be quantified by comparing the drug concentrations required to achieve 50% inhibition (IC50​) of each enzyme. For celecoxib, the IC50​ for COX-2 is approximately 0.05 µM, whereas the IC50​ for COX-1 is 22.9 µM.[9] This represents a selectivity ratio of over 400-fold in favor of COX-2, confirming its high degree of specificity at clinically relevant doses.

Ancillary and Investigational Mechanisms

Research has revealed that celecoxib's biological activity may extend beyond COX-2 inhibition, involving several ancillary mechanisms that are areas of active investigation, particularly in oncology and neuroscience.

• Induction of Apoptosis: Celecoxib has been demonstrated to induce apoptosis, or programmed cell death, in a variety of cancer cell lines in a concentration-dependent manner, including human osteosarcoma and lymphoma cells.[6] This effect may be mediated through a novel mitochondrial signaling pathway, suggesting a mechanism independent of prostaglandin synthesis inhibition.[9]
• Cadherin-11 Binding: Further supporting its potential role in oncology, celecoxib has been found to bind to cadherin-11 (CDH11), an adhesion protein that is believed to be involved in the malignant progression and metastasis of certain cancer cells.[10]
• Neuroscience Effects: In preclinical models, celecoxib has shown effects on neuronal pathways. For instance, in a rat model of diabetes-induced cognitive impairment, celecoxib treatment was found to alleviate memory deficits. This effect was associated with the downregulation of COX-2 expression in the brain but also, perhaps more importantly, with the upregulation of the brain-derived neurotrophic factor (BDNF) and its receptor, tropomyosin-related kinase B (TrkB), a signaling pathway crucial for neuronal survival and synaptic plasticity.[9]

The existence of these COX-2-independent mechanisms suggests that celecoxib may function as a multi-target agent. This possibility complicates its pharmacological profile but also helps to explain the persistent scientific interest in its potential application for cancer chemoprevention and as an adjunctive therapy in psychiatric disorders, where inflammatory and other pathways are implicated.[18]

Pharmacokinetics

The pharmacokinetic profile of celecoxib describes its journey through the body—absorption, distribution, metabolism, and elimination (ADME)—which is governed by its physicochemical properties and its interaction with metabolic enzymes.

Absorption

Following oral administration, celecoxib is rapidly absorbed from the gastrointestinal tract.[1] Under fasting conditions, peak plasma concentrations (

Tmax​) are typically achieved within 3 hours.[1] A single 200 mg oral dose administered to healthy subjects yields a maximum plasma concentration (

Cmax​) of approximately 705 ng/mL.[1]

The absorption of celecoxib is influenced by food, a characteristic directly related to its low aqueous solubility (BCS Class 2). When taken with a high-fat meal, the time to reach peak plasma levels is delayed by about 1 to 2 hours, and the total drug exposure, as measured by the area under the curve (AUC), is increased by 10% to 20%.[8] The drug's pharmacokinetics are approximately dose-proportional for both

Cmax​ and AUC at doses up to 200 mg twice daily. However, at higher doses, there are less-than-proportional increases in these parameters, an effect also attributed to the low solubility of the drug, which becomes a rate-limiting factor for absorption at higher concentrations.[11]

Distribution

Once absorbed into the bloodstream, celecoxib is extensively distributed throughout the body's tissues. This is evidenced by its large apparent volume of distribution at steady state (Vss​/F), which is approximately 400 to 455 L.[8] This large volume suggests significant partitioning from the plasma into peripheral tissues. Within the clinical dose range, celecoxib is highly bound to plasma proteins (approximately 97%), primarily to albumin and, to a lesser extent, to α1-acid glycoprotein.[8] This high degree of protein binding is a key factor in its disposition and limits its removal by hemodialysis.[1]

Metabolism

Celecoxib is eliminated from the body almost entirely through extensive metabolic conversion, which occurs predominantly in the liver.[1] The primary enzyme responsible for its metabolism is the cytochrome P450 isoenzyme

CYP2C9.[8] The CYP3A4 isoenzyme also contributes to a minor extent (less than 25% of the metabolic pathway).[18]

The metabolic process begins with the hydroxylation of the methyl group on the tolyl moiety, forming a primary alcohol metabolite known as hydroxycelecoxib. This intermediate is then further oxidized by cytosolic alcohol dehydrogenases (ADH1 and ADH2) to its corresponding carboxylic acid, carboxycelecoxib. Finally, this acid metabolite can undergo conjugation with glucuronic acid to form celecoxib glucuronide.[1] A critical pharmacodynamic point is that all of these major metabolites identified in human plasma are pharmacologically inactive; they do not inhibit either COX-1 or COX-2.[14]

Elimination

The elimination of celecoxib is driven by its hepatic metabolism. An extremely small fraction of the administered dose (less than 3%) is excreted unchanged in both the urine and feces.[1] Following an oral dose, approximately 57% is recovered in the feces and 27% in the urine, almost entirely in the form of its various metabolites.[1] The primary metabolite found in both urine and feces is the inactive carboxylic acid derivative.[1] The effective elimination half-life (

t1/2​) of celecoxib in healthy subjects is approximately 11 hours, which supports a once- or twice-daily dosing regimen.[1] The terminal half-life can appear prolonged due to its low solubility, which can create a "flip-flop" pharmacokinetic profile where the rate of absorption, rather than elimination, becomes the rate-limiting step in drug clearance from the plasma.[1]

Pharmacogenomics and Special Populations

The heavy reliance of celecoxib on a single primary metabolic pathway, CYP2C9, is a central feature of its clinical pharmacology and a major source of inter-individual variability in drug response and toxicity. The gene encoding the CYP2C9 enzyme is known to be polymorphic, with certain alleles (e.g., CYP2C9*3) resulting in significantly reduced enzyme activity. Individuals who inherit two of these variant alleles are classified as "poor metabolizers".[18]

This genetic variation has direct and clinically significant consequences. Patients who are CYP2C9 poor metabolizers are unable to clear celecoxib from their system at a normal rate. This leads to a substantial increase in systemic drug exposure—with AUC values reported to be several-fold higher than in individuals with normal enzyme function ("extensive metabolizers").[11] Because many of celecoxib's adverse effects are dose- and concentration-dependent, this genetically determined increase in exposure places poor metabolizers at a significantly higher risk for toxicity, including GI, cardiovascular, and renal events.

This well-understood relationship between genotype and drug exposure has led to specific clinical recommendations. For patients who are known or suspected to be CYP2C9 poor metabolizers, it is advised to initiate celecoxib therapy at 50% of the lowest recommended dose.[21] For pediatric patients with this genetic profile, consideration of an alternative medication may be more appropriate.[21] This represents a key example of pharmacogenomics being translated into actionable clinical guidance to enhance drug safety. This genetic susceptibility can be further compounded by pharmacological factors; co-administration of a potent CYP2C9 inhibitor, such as the antifungal drug fluconazole, in any patient (but especially in a poor metabolizer) can lead to a dramatic and potentially dangerous elevation in celecoxib plasma levels.[18]

Clinical Efficacy and Therapeutic Applications

Celecoxib has been evaluated in numerous clinical trials, establishing its efficacy in a range of inflammatory and pain-related conditions. Its use is well-defined by several FDA-approved indications, while ongoing research continues to explore its potential in various off-label settings.

FDA-Approved Indications

Celecoxib is officially indicated by the U.S. Food and Drug Administration (FDA) for the treatment of multiple musculoskeletal, pain, and inflammatory disorders.

• Osteoarthritis (OA): Celecoxib is approved for the symptomatic treatment of adult osteoarthritis, providing relief from joint pain and inflammation.[1] Clinical trials lasting up to 12 weeks have demonstrated a significant reduction in joint pain compared to placebo, establishing it as a standard therapeutic option.[3]
• Rheumatoid Arthritis (RA): It is indicated for the symptomatic management of adult rheumatoid arthritis, an autoimmune condition characterized by chronic joint inflammation.[1]
• Juvenile Idiopathic Arthritis (JIA): Formerly known as Juvenile Rheumatoid Arthritis (JRA), celecoxib is approved for use in pediatric patients aged 2 years and older.[1] Its safety and efficacy have not been established in children younger than 2 years or in those weighing less than 10 kg.[16]
• Ankylosing Spondylitis (AS): The drug is indicated for managing the signs and symptoms of ankylosing spondylitis, a type of inflammatory arthritis that primarily affects the spine.[1] This indication was granted FDA approval in 2005.[25]
• Acute Pain: Celecoxib is approved for the management of acute pain in adults.[1] This broad indication covers pain from various etiologies, including musculoskeletal injuries like sprains and strains, post-surgical pain (e.g., following oral surgery), and some types of headaches.[24]
• Primary Dysmenorrhea: It is indicated for the treatment of pain associated with menstrual cramps.[1]
• Acute Migraine: A specific formulation, the 25 mg/mL oral solution (Elyxyb), is approved for the acute treatment of migraine with or without aura in adults.[4] A pivotal Phase III clinical trial confirmed its superiority over placebo, with a significantly higher proportion of patients achieving freedom from pain and freedom from their most bothersome migraine-associated symptom (nausea, photophobia, or phonophobia) at 2 hours post-dose.[27]
• Familial Adenomatous Polyposis (FAP): Celecoxib holds a unique indication as an adjunctive therapy to standard care (such as endoscopic surveillance and surgery) to reduce the number of adenomatous colorectal polyps in patients with the hereditary condition FAP.[1] This approval was granted in 1999 based on evidence of its chemopreventive effects.[25] However, this indication exemplifies a complex clinical risk-benefit scenario. The Adenoma Prevention with Celecoxib (APC) trial, which supported this use, demonstrated that celecoxib significantly reduces the recurrence of precancerous adenomas.[19] The same trial, however, also revealed a dose-dependent and statistically significant increase in the risk of serious cardiovascular thrombotic events.[22] This finding was instrumental in the FDA's decision to mandate a boxed warning for the entire NSAID class. Consequently, prescribing celecoxib for the long-term prophylactic purpose of polyp reduction in FAP patients requires a careful and individualized assessment, weighing the demonstrated chemopreventive benefit against a substantial increase in cardiovascular risk.

Off-Label and Investigational Uses

Beyond its approved indications, celecoxib is frequently used "off-label" for other conditions, supported by varying levels of clinical evidence. It also remains a subject of active research for novel applications.

• Acute Gout: One of the most common and well-supported off-label uses of celecoxib is for the management of acute gouty arthritis flares.[10] Gout is an intensely painful inflammatory condition caused by the deposition of urate crystals in joints. A major Phase 3, multicenter, randomized, double-blind clinical trial (NCT00549549) was conducted to formally evaluate this use.[29] The study compared a high-dose celecoxib regimen (800 mg initial dose, followed by 400 mg later on day 1, then 400 mg twice daily) against the traditional non-selective NSAID indomethacin, a standard treatment for acute gout.[31] The results showed that high-dose celecoxib was comparable in efficacy to indomethacin for reducing the severe pain of a gout flare. Critically, however, the celecoxib group experienced significantly fewer adverse events and had a lower rate of treatment discontinuation due to side effects compared to the indomethacin group.[31] This high-quality evidence provides a strong rationale for using celecoxib as a potentially safer, better-tolerated alternative to traditional NSAIDs for this painful condition.
• Psychiatry (Adjunctive Therapy): There is growing interest in the role of neuroinflammation in the pathophysiology of major psychiatric disorders, which has prompted investigation into the use of anti-inflammatory agents like celecoxib as adjunctive treatments.[19]
• Major Depressive Disorder (MDD): Evidence is most promising in this area. A 2014 meta-analysis of randomized controlled trials concluded that adding celecoxib (typically at 400 mg/day for 6 weeks) to standard antidepressant therapy significantly improved depressive symptoms and increased rates of treatment response and remission compared to antidepressant therapy plus placebo.[19]
• Schizophrenia: The evidence here is more controversial. Some randomized, placebo-controlled add-on trials have suggested a benefit, particularly in the early stages of the illness.[32] One notable 5-week trial found that adding 400 mg/day of celecoxib to the antipsychotic risperidone led to a significantly greater improvement in overall psychopathology scores compared to risperidone alone.[34] However, results across studies have been inconsistent.
• Bipolar Disorder: The data for bipolar disorder are currently inconclusive. Meta-analyses have been hampered by low-quality evidence and have not found a clear signal of efficacy, particularly for bipolar depression.[19]

The potential use of an anti-inflammatory agent as a psychiatric medication represents a novel therapeutic paradigm. While the positive signals in MDD are intriguing, this application is not yet considered standard of care.35 The long-term cardiovascular and gastrointestinal risks associated with chronic NSAID use are a significant concern that must be carefully weighed against the potential benefits in this patient population, and further research is required.

• Cancer Chemoprevention and Treatment: As noted previously, celecoxib's ability to induce apoptosis and its effects on pathways beyond COX-2 have made it a candidate for cancer research.[6] Its approved use in FAP is a direct outcome of this line of investigation.
• Other Investigational Uses: Celecoxib continues to be evaluated for other conditions. Phase 4 clinical trials are actively recruiting patients to study its efficacy in shoulder pain.[36] An open-label study is underway to assess a fixed-dose combination of ciprofloxacin and celecoxib (known as PrimeC) for the treatment of amyotrophic lateral sclerosis (ALS).[37] Additionally, it has been shown to be a safe and effective adjunctive therapy for treating chronic synovitis and joint pain associated with hemophilia.[16]

Dosage, Administration, and Formulations

The effective and safe use of celecoxib requires adherence to specific dosing guidelines, which vary by indication and patient population. Proper administration techniques and awareness of available formulations are also essential for optimal outcomes.

Dosing and Administration Guidelines

The cardinal principle for all NSAID therapy, including celecoxib, is to use the lowest effective dose for the shortest duration consistent with individual patient treatment goals.[21] This strategy is paramount for minimizing the risk of dose- and duration-dependent adverse effects, particularly cardiovascular and gastrointestinal events.

Celecoxib capsules can be administered with or without regard to the timing of meals.[14] However, taking higher doses (e.g., 400 mg twice daily) with food is recommended, as this can help improve the absorption of the poorly soluble drug.[21] For patients who have difficulty swallowing capsules, a common issue in pediatric and geriatric populations, the contents of a celecoxib capsule can be carefully emptied onto a level teaspoon of cool or room-temperature applesauce. The mixture should be ingested immediately, followed by water, to ensure the full dose is delivered.[21] This sprinkled mixture is stable for up to 6 hours when refrigerated.[22] In addition to capsules, an oral solution (Elyxyb) is available specifically for the treatment of acute migraine.[4]

Indication	Population	Recommended Dosage	Notes	Source(s)
Osteoarthritis	Adults	200 mg once daily OR 100 mg twice daily	-	22
Rheumatoid Arthritis	Adults	100 mg to 200 mg twice daily	-	22
Juvenile Idiopathic Arthritis	Children (≥2 years)	10 kg to ≤25 kg: 50 mg twice daily>25 kg: 100 mg twice daily	Dosing is weight-based.	20
Ankylosing Spondylitis	Adults	200 mg once daily (single or divided dose)	If no effect after 6 weeks, a trial of 400 mg daily may be considered. Discontinue if no effect after another 6 weeks.	22
Acute Pain & Primary Dysmenorrhea	Adults	400 mg initial dose, followed by an additional 200 mg dose if needed on Day 1. On subsequent days, 200 mg twice daily as needed.	Utilizes a higher loading dose for rapid onset of analgesia.	22
Acute Migraine	Adults	120 mg once daily (oral solution)	This dose is specific to the Elyxyb formulation.	23

Dosing in Special Populations

Dose adjustments are necessary for certain patient populations to account for physiological differences that affect drug pharmacokinetics and tolerability.

• Pediatric Population: Dosing for JIA in children 2 years and older is strictly based on body weight, as outlined in Table 5.1.[20] Celecoxib is not established as safe or effective in children under 2 years of age or those weighing less than 10 kg.[16]
• Geriatric Population: While no specific dose adjustment is mandated for the elderly, caution is strongly advised. Geriatric patients are more susceptible to the adverse effects of NSAIDs due to a higher prevalence of age-related decline in cardiac, renal, and hepatic function, as well as a greater risk of comorbidities and polypharmacy.[23] They are at a particularly high risk for serious GI events.[28]
• Hepatic Impairment: Dose modification is critical in patients with impaired liver function. This is a direct consequence of celecoxib's extensive hepatic metabolism for clearance.[1] In patients with moderate hepatic impairment (Child-Pugh Class B), drug clearance is significantly reduced, leading to an approximate 180% increase in total drug exposure (AUC).[11] To normalize this exposure and mitigate the risk of toxicity, the recommended daily dose should be reduced by 50%.[20] The use of celecoxib is not recommended or is contraindicated in patients with severe hepatic impairment (Child-Pugh Class C).[20]
• Renal Impairment: For patients with mild to moderate renal impairment, celecoxib should be used with caution.[20] Interestingly, studies have shown that the AUC of celecoxib may be lower in this population, with an increased apparent clearance, a finding that may be related to alterations in protein binding or other compensatory mechanisms.[1] Despite this, caution is still warranted due to the potential for all NSAIDs to cause renal toxicity. Use of celecoxib is not recommended or should be avoided in patients with severe renal impairment (Creatinine Clearance, CrCl<30mL/min).[10] Due to its high protein binding, celecoxib is unlikely to be removed by hemodialysis.[1]
• CYP2C9 Poor Metabolizers: As discussed in the pharmacokinetics section, patients with genetically determined poor CYP2C9 metabolism have significantly increased exposure to celecoxib. For adult patients known or suspected to be poor metabolizers, it is recommended to initiate therapy at 50% of the lowest recommended dose to prevent excessive drug accumulation and potential toxicity.[21]

Safety Profile and Risk Management

The safety profile of celecoxib is complex, characterized by a well-defined class-wide risk for all NSAIDs, alongside a specific profile related to its COX-2 selectivity. Effective risk management requires a thorough understanding of its most serious potential harms, contraindications, adverse reactions, and drug interactions.

FDA Boxed Warnings: Cardiovascular and Gastrointestinal Risks

The most critical safety concerns for celecoxib are highlighted in FDA-mandated boxed warnings, the agency's strongest form of warning, which address both cardiovascular and gastrointestinal risks.

Cardiovascular (CV) Thrombotic Events

• The Warning: All NSAIDs, including celecoxib, may cause an increased risk of serious and potentially fatal cardiovascular thrombotic events, including myocardial infarction (MI) and stroke.[14] This risk can occur early in treatment and may increase with the duration of use. Patients with pre-existing cardiovascular disease or risk factors for cardiovascular disease (e.g., hypertension, hyperlipidemia) may be at greater risk.[14]
• Historical Context and the PRECISION Trial: The concern over the cardiovascular safety of COX-2 inhibitors was amplified by the market withdrawal of rofecoxib (Vioxx) in 2004 due to clear evidence of increased thrombotic risk.[17] This event cast a shadow over the entire class and led the FDA to mandate boxed warnings for all NSAIDs in 2005.[41] To better quantify celecoxib's specific risk, a large, long-term, randomized post-marketing study called the "Prospective Randomized Evaluation of Celecoxib Integrated Safety vs. Ibuprofen or Naproxen" (PRECISION) trial was conducted.[42] This landmark trial enrolled over 24,000 patients with arthritis at high cardiovascular risk. The results, published in 2016, found that moderate doses of celecoxib (average dose of 209 mg/day) were non-inferior to both ibuprofen and naproxen with respect to the primary composite outcome of cardiovascular death, non-fatal MI, or non-fatal stroke.[42] This trial was pivotal, as it provided robust evidence that celecoxib's cardiovascular risk is comparable to that of commonly used non-selective NSAIDs, rather than being inherently greater. This finding does not eliminate the risk but reframes the clinical decision from avoiding a uniquely dangerous drug to selecting among several agents that share a similar, known class-wide risk.

Gastrointestinal (GI) Bleeding, Ulceration, and Perforation

• The Warning: NSAIDs, including celecoxib, cause an increased risk of serious gastrointestinal adverse events, including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal.[16] These events can occur at any time during use and without warning symptoms. Elderly patients are at a greater risk for these events.[28]
• The Central Therapeutic Trade-Off: This warning must be interpreted in the context of celecoxib's primary therapeutic advantage. While celecoxib does carry a risk of GI toxicity, its selective inhibition of COX-2 means that this risk is significantly lower than that associated with non-selective NSAIDs like naproxen and ibuprofen.[1] Numerous studies, including large-scale trials like CLASS, have confirmed a lower incidence of endoscopic ulcers and clinically significant GI bleeds with celecoxib.[3] The two boxed warnings thus encapsulate the core clinical dilemma of celecoxib: the prescriber must weigh the benefit of improved GI safety against a cardiovascular risk that is comparable to other NSAIDs. The decision to use celecoxib is often made to prioritize GI protection in a patient deemed to be at high risk for GI complications (e.g., older age, history of peptic ulcer disease, concurrent use of anticoagulants or corticosteroids).

Contraindications and Clinically Significant Precautions

There are several absolute contraindications and situations where celecoxib must be used with significant caution.

• Absolute Contraindications:
• Patients with a known hypersensitivity to celecoxib, any of its components, or other sulfonamides. The sulfonamide moiety in celecoxib's structure is the basis for this contraindication.[20]
• Patients with a history of aspirin- or NSAID-induced hypersensitivity reactions, such as asthma, urticaria (hives), or other allergic-type reactions.[20]
• For the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery, due to an increased risk of MI and stroke in this setting.[20]
• Precautions (Use with Caution):
• Cardiovascular Disease: Patients with pre-existing hypertension, congestive heart failure, or edema (fluid retention).[23]
• Gastrointestinal Risk Factors: Patients with a prior history of peptic ulcer disease or GI bleeding, as well as those who consume alcohol or smoke.[23]
• Renal Disease: Patients with pre-existing renal impairment, dehydration, hypovolemia, or heart failure, as NSAIDs can precipitate acute renal decompensation.[16]
• Hepatic Disease: Patients with pre-existing liver impairment.[20]
• Asthma: Patients with asthma, particularly those with aspirin-sensitive asthma, may experience bronchospasm.[39]
• Pregnancy: NSAID use should be avoided after 20 weeks of gestation due to the risk of fetal renal dysfunction leading to oligohydramnios. Use is contraindicated after 30 weeks of gestation due to the risk of premature closure of the fetal ductus arteriosus.[10]

Adverse Drug Reactions

While generally well-tolerated, celecoxib is associated with a range of potential adverse effects, from common, mild symptoms to rare, life-threatening events.[10]

• Common Adverse Events (≥2% incidence): The most frequently reported adverse reactions are primarily gastrointestinal and central nervous system-related. These include dyspepsia (8.8%), diarrhea (5.6%), abdominal pain (4.1%), nausea (3.5%), flatulence (2.2%), and headache (15.8%).[20]
• Serious Adverse Events:
• Cardiovascular and Gastrointestinal: As detailed in the boxed warnings.
• Hepatotoxicity: Elevations in liver transaminases (AST, ALT) can occur. While typically mild, rare cases of severe hepatic reactions, including jaundice and fatal fulminant hepatitis, have been reported.[10]
• Hypertension: Celecoxib can lead to new-onset hypertension or the worsening of pre-existing hypertension, requiring regular blood pressure monitoring.[10]
• Heart Failure and Edema: Fluid retention and edema can occur, potentially exacerbating congestive heart failure.[14]
• Renal Toxicity: NSAIDs can cause direct renal injury, including interstitial nephritis and renal papillary necrosis, particularly in at-risk patients.[10]
• Anaphylactic Reactions: Severe allergic reactions can occur, even in patients without prior known sensitivity.[10]
• Serious Skin Reactions: Rare but potentially fatal skin reactions, including Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), have been reported.[10]

Drug-Drug Interactions

Celecoxib is subject to a large number of clinically significant drug-drug interactions, stemming from both its pharmacokinetic properties (as a CYP2C9 substrate) and its pharmacodynamic effects (as an NSAID).[51]

Interacting Drug/Class	Mechanism of Interaction	Clinical Consequence	Management Recommendation	Source(s)
CYP2C9 Inhibitors (e.g., Fluconazole)	Inhibition of celecoxib's primary metabolic enzyme (CYP2C9).	Two-fold or greater increase in celecoxib plasma concentrations, increasing risk of dose-related toxicity.	Use with caution. Consider reducing celecoxib dose by 50%.	14
Anticoagulants (e.g., Warfarin) & Antiplatelets (e.g., Aspirin, Clopidogrel)	Pharmacodynamic synergism. Additive risk of bleeding due to NSAID-induced GI mucosal injury.	Significantly increased risk of serious gastrointestinal bleeding.	Avoid combination if possible. If necessary, monitor closely for signs of bleeding. Monitor INR for warfarin. Celecoxib is not a substitute for low-dose aspirin for CV prophylaxis.	1
Other NSAIDs (e.g., Ibuprofen, Naproxen)	Additive pharmacodynamic effects (COX inhibition).	Increased risk of GI ulceration and other NSAID-related adverse events with no added therapeutic benefit.	Concomitant use should be avoided.	20
ACE Inhibitors, ARBs, Diuretics (e.g., Furosemide)	Inhibition of renal prostaglandin synthesis, which blunts the effects of these drugs.	Diminished antihypertensive and natriuretic (salt-excreting) effects. Increased risk of renal impairment.	Monitor blood pressure and renal function closely.	14
Lithium	NSAIDs can reduce the renal clearance of lithium.	Increased plasma lithium concentrations, leading to a higher risk of lithium toxicity.	Monitor lithium levels closely when celecoxib is initiated, adjusted, or discontinued.	11
Alcohol	Additive risk of gastric mucosal irritation.	Increased risk of stomach bleeding.	Advise patients to limit or avoid alcohol consumption while taking celecoxib.	39
Corticosteroids (e.g., Prednisone)	Additive risk of gastrointestinal toxicity.	Increased risk of GI ulceration and bleeding.	Use combination with caution and for the shortest duration possible.	52

Comparative Analysis and Therapeutic Context

To fully appreciate the clinical role of celecoxib, it must be viewed in comparison to other anti-inflammatory agents and within the historical context of its drug class.

Comparison with Non-Selective NSAIDs (Ibuprofen, Naproxen)

The choice between celecoxib and a traditional, non-selective NSAID like ibuprofen or naproxen involves a multi-faceted comparison of efficacy, safety, and cost.

• Efficacy: For their approved indications in treating pain and inflammation in conditions like osteoarthritis and rheumatoid arthritis, celecoxib is generally considered to have comparable efficacy to standard doses of non-selective NSAIDs.[8] No agent has been consistently shown to be superior in terms of pure analgesic or anti-inflammatory effect.
• Gastrointestinal (GI) Safety: This is the primary point of differentiation and celecoxib's main advantage. Due to its selective inhibition of COX-2 and relative sparing of the protective COX-1 enzyme, celecoxib is associated with a significantly lower incidence of GI side effects. This includes a reduced risk of developing endoscopic ulcers, symptomatic ulcers, and clinically significant upper GI bleeding compared to ibuprofen and naproxen.[1] This gastropreserving effect is the principal reason for choosing celecoxib over a non-selective agent.
• Cardiovascular (CV) Safety: For many years, it was presumed that selective COX-2 inhibitors carried a higher intrinsic CV risk than traditional NSAIDs. However, the landmark PRECISION trial demonstrated that the risk of major adverse cardiovascular events with moderate-dose celecoxib is non-inferior to that of ibuprofen and naproxen.[42] Therefore, while all these agents carry a CV risk, celecoxib is not considered to be worse than its common non-selective counterparts in this regard.
• Renal Effects and Blood Pressure: The potential for nephrotoxicity, fluid retention, and elevation of blood pressure are class-wide effects for all NSAIDs, including celecoxib.[46] These effects are mediated by the inhibition of renal prostaglandins and are a concern with any agent in this class, particularly in at-risk patients.
• Availability and Cost: A major practical difference is accessibility and cost. Ibuprofen and naproxen are widely available over-the-counter (OTC) at low cost, with higher strengths available by prescription.[44] Celecoxib is available only by prescription.[44] Even in its generic form, celecoxib is substantially more expensive than OTC or prescription generic non-selective NSAIDs.[54] This cost differential is often a significant factor in clinical decision-making and formulary placement.

The COX-2 Inhibitor Class: A Historical and Clinical Perspective

Celecoxib belongs to a class of drugs known as "coxibs," which were specifically designed in the 1990s to be selective COX-2 inhibitors.[25] The history of this class is crucial for understanding the intense regulatory and clinical scrutiny that celecoxib has faced throughout its existence.

Celecoxib is currently the only orally administered selective COX-2 inhibitor available in the United States.[17] Two other prominent members of this class,

rofecoxib (Vioxx) and valdecoxib (Bextra), were voluntarily withdrawn from the global market by their manufacturers in 2004 and 2005, respectively.[17] These withdrawals were prompted by accumulating data from clinical trials that demonstrated a clear and significant increase in the risk of serious cardiovascular events, particularly heart attack and stroke, associated with their long-term use.[17]

The withdrawal of Vioxx, in particular, was a watershed moment in pharmaceutical history. It created a powerful perception of a negative "class effect," leading to the assumption that all selective COX-2 inhibitors inherently carried an unacceptable level of cardiovascular risk. This legacy has profoundly shaped the clinical narrative and regulatory posture towards celecoxib. It directly led to the FDA's 2005 mandate for stringent boxed warnings on all NSAIDs and spurred the requirement for large, long-term cardiovascular safety studies like the PRECISION trial to better define celecoxib's specific risk profile.[41] Understanding this history is essential to appreciating why the cardiovascular risk of celecoxib is always a primary point of discussion and why it is positioned as a second-line agent for many patients, despite its clear GI benefits.

Regulatory and Commercial Landscape

The journey of celecoxib from development to its current market position has been shaped by key regulatory decisions and commercial factors.

Regulatory History and Key Milestones

• Development and Initial Approval: Celecoxib was developed by G.D. Searle & Company, which was later involved in a series of corporate mergers and acquisitions that ultimately placed the molecule under the ownership of Pfizer.[25]
• December 31, 1998: The U.S. FDA granted initial approval for Celebrex for the symptomatic treatment of Osteoarthritis (OA) and Rheumatoid Arthritis (RA).[3]
• 1999: The FDA expanded its approved uses to include Familial Adenomatous Polyposis (FAP) for polyp reduction. In the same year, a warning was added to the label regarding a potential interaction with the anticoagulant warfarin.[25]
• April 2005: In the wake of the Vioxx withdrawal, the FDA took broad action across the NSAID class. It mandated that the Celebrex label be revised to include a boxed warning highlighting the risks of both cardiovascular and gastrointestinal events.[25] Also in 2005, the FDA approved celecoxib for the treatment of Ankylosing Spondylitis (AS).[25]
• 2006: The FDA granted approval for the treatment of Juvenile Rheumatoid Arthritis (JRA) in children 2 years and older.[25]
• June 2018: The FDA approved a labeling supplement for Celebrex to officially incorporate the results of the PRECISION cardiovascular outcomes trial, which provided data on its relative safety compared to ibuprofen and naproxen.[42]
• May 2020: A new formulation, Elyxyb (celecoxib oral solution), received FDA approval for the acute treatment of migraine.[4]
• October 2021: The FDA approved Seglentis, a novel co-crystal formulation combining celecoxib and the opioid analgesic tramadol, for the management of acute pain. This product has subsequently been discontinued.[57]

Commercial Status, Formulations, and Cost Analysis

• Brand and Generic Status: Celecoxib is available both as the brand-name product Celebrex and as a lower-cost generic medication.[26] The availability of a generic version has increased its accessibility, and it is covered by most Medicare and insurance plans.[59]
• Available Formulations:
• Oral Capsules: The most common formulation, available in strengths of 50 mg, 100 mg, 200 mg, and 400 mg.[22]
• Oral Solution: A 25 mg/mL solution is marketed as Elyxyb for acute migraine.[4]
• Cost Comparison: Despite the availability of a generic, the cost of celecoxib remains a significant consideration in clinical practice.
• Generic celecoxib is substantially more expensive than the widely available OTC non-selective NSAIDs, ibuprofen and naproxen.[53]
• Cash prices can vary widely depending on the pharmacy, insurance plan, and use of discount coupons. For a 30-day supply of 200 mg capsules, the retail price of generic celecoxib can range from approximately $11 to over $200.[45] In contrast, a similar supply of prescription-strength ibuprofen or naproxen typically costs between $6 and $40.[53]
• This significant cost difference often acts as a practical barrier, positioning celecoxib as a preferred option primarily for patients with specific risk factors (i.e., high GI risk) for whom the added cost is justified by the potential to avoid a serious GI complication, or for patients who have failed or cannot tolerate cheaper alternatives.

Expert Synthesis and Conclusion

Celecoxib occupies a distinct and important niche in the modern therapeutic armamentarium for pain and inflammation. Its clinical value is rooted in its selective inhibition of the COX-2 enzyme, a mechanism that successfully uncouples the potent anti-inflammatory and analgesic effects of NSAIDs from much of the gastrointestinal toxicity that plagues traditional, non-selective agents. The primary role for celecoxib in contemporary practice is, therefore, as an effective treatment for patients with chronic arthritic conditions and acute pain who are at a demonstrably high risk for developing serious NSAID-induced gastrointestinal complications, such as peptic ulcers and bleeding.

However, the therapeutic application of celecoxib is governed by a crucial and unavoidable clinical trade-off. The benefit of improved GI safety must be carefully weighed against a known risk of serious cardiovascular thrombotic events. The perception of this risk has evolved significantly over time. While once feared to be inherently greater than that of traditional NSAIDs due to the history of the coxib class, large-scale, long-term data from the PRECISION trial have clarified that the cardiovascular risk of moderate-dose celecoxib is comparable, but not superior, to that of ibuprofen and naproxen. This establishes the risk as a class-wide effect of NSAIDs rather than a unique danger of celecoxib, but it does not eliminate the concern.

This safety profile mandates a highly individualized approach to prescribing. The guiding principles must always be the use of the lowest effective dose for the shortest possible duration, tailored to the specific treatment goals of the patient. Optimal patient selection is paramount, focusing on those for whom the GI benefits are most likely to outweigh the inherent cardiovascular risks.

Furthermore, a sophisticated understanding of celecoxib's pharmacokinetics is essential for its safe use. Its primary reliance on the polymorphic CYP2C9 enzyme for metabolism is a key source of inter-patient variability. The existence of CYP2C9 "poor metabolizers," who experience significantly elevated drug exposure, represents a tangible area for personalized medicine, where pharmacogenomic testing and proactive dose reduction can directly mitigate the risk of toxicity.

Finally, while the established indications for celecoxib are clear, its investigational uses in areas such as adjunctive psychiatric therapy and oncology highlight its complex pharmacology and point toward intriguing future possibilities. These applications, driven by the drug's effects on neuroinflammation and cellular apoptosis, are promising but remain largely experimental. They require substantially more robust clinical data to validate their efficacy and, critically, to assess the long-term risk-benefit balance before they can be considered for standard clinical practice.

In conclusion, celecoxib remains a valuable therapeutic tool. It is not a universally superior NSAID, but rather a specialized agent whose benefits are maximized when used judiciously and selectively in well-defined patient populations, with a constant and vigilant appreciation for its complex safety profile and the central risk-benefit equation that defines its use.

Works cited

1. Celecoxib: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed July 14, 2025, https://go.drugbank.com/drugs/DB00482
2. Celecoxib | C17H14F3N3O2S - ChemSpider, accessed July 14, 2025, https://www.chemspider.com/Chemical-Structure.2562.html
3. FDA Approves Celecoxib Celebrex • Johns Hopkins Arthritis Center, accessed July 14, 2025, https://www.hopkinsarthritis.org/arthritis-news/fda-approves-celecoxib-celebrex/
4. FDA Approves Celecoxib in an Oral Solution - The Rheumatologist, accessed July 14, 2025, https://www.the-rheumatologist.org/article/fda-approves-celecoxib-in-an-oral-solution/
5. Celecoxib | C17H14F3N3O2S | CID 2662 - PubChem, accessed July 14, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Celecoxib
6. Celecoxib | 169590-42-5 | FC11300 - Biosynth, accessed July 14, 2025, https://www.biosynth.com/p/FC11300/169590-42-5-celecoxib
7. Celecoxib 169590-42-5 | TCI AMERICA - Tokyo Chemical Industry, accessed July 14, 2025, https://www.tcichemicals.com/US/en/p/C2816
8. Celecoxib | 169590-42-5 - ChemicalBook, accessed July 14, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB7444681.htm
9. Celecoxib (CAS 169590-42-5) - Cayman Chemical, accessed July 14, 2025, https://www.caymanchem.com/product/10008672/celecoxib
10. Celecoxib - StatPearls - NCBI Bookshelf, accessed July 14, 2025, https://www.ncbi.nlm.nih.gov/books/NBK535359/
11. Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor - PubMed, accessed July 14, 2025, https://pubmed.ncbi.nlm.nih.gov/10749518/
12. celebrex - accessdata.fda.gov, accessed July 14, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20998lbl.pdf
13. Celecoxib - PMDA, accessed July 14, 2025, https://www.pmda.go.jp/files/000231272.pdf
14. CELEBREX celecoxib capsules Cardiovascular Risk - accessdata.fda.gov, accessed July 14, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020998s026lbl.pdf?ref=fs38l1
15. www.ncbi.nlm.nih.gov, accessed July 14, 2025, https://www.ncbi.nlm.nih.gov/books/NBK535359/#:~:text=The%20mechanism%20of%20celecoxib's%20action,%2Dinflammatory%2C%20and%20antipyretic%20effects.
16. Celebrex - FepBlue, accessed July 14, 2025, https://www.fepblue.org/-/media/PDFs/Medical-Policies/2024/March/Mar-2024-Pharmacy-Policies/Remove---Replace/570006-Celebrex-celecoxib.pdf
17. List of COX-2 Inhibitors + Uses, Types & Side Effects - Drugs.com, accessed July 14, 2025, https://www.drugs.com/drug-class/cox-2-inhibitors.html
18. Celecoxib Pathway, Pharmacokinetics - PharmGKB, accessed July 14, 2025, https://www.pharmgkb.org/pathway/PA165816736
19. Celecoxib - Wikipedia, accessed July 14, 2025, https://en.wikipedia.org/wiki/Celecoxib
20. Celecoxib - Mechanism, Indication, Contraindications, Dosing, Adverse Effect, Interaction, Renal Dose, Hepatic Dose | Drug Index | Pediatric Oncall, accessed July 14, 2025, https://www.pediatriconcall.com/drugs/celecoxib/391
21. Celebrex Dosage Guide: How Much Should I Take for Pain? - GoodRx, accessed July 14, 2025, https://www.goodrx.com/celebrex/dosage
22. CELECOXIB - DailyMed, accessed July 14, 2025, https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d4a9aaeb-bd5e-4a69-b26d-4ede84cb4166&type=display
23. Celecoxib (oral route) - Mayo Clinic, accessed July 14, 2025, https://www.mayoclinic.org/drugs-supplements/celecoxib-oral-route/description/drg-20068925
24. About Celebrex (Celecoxib), a COX-2 Inhibitor - Spine-health, accessed July 14, 2025, https://www.spine-health.com/treatment/pain-medication/about-celebrex-celecoxib-cox-2-inhibitor
25. Celecoxib History - News-Medical.net, accessed July 14, 2025, https://www.news-medical.net/health/Celecoxib-History.aspx
26. Celebrex (celecoxib): Side effects, uses, dosage, and more - Medical News Today, accessed July 14, 2025, https://www.medicalnewstoday.com/articles/celebrex
27. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Tolerability, and Safety of Celecoxib Oral Solution (ELYXYB) in Acute Treatment of Episodic Migraine with or without Aura - PubMed Central, accessed July 14, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8382884/
28. CELEBREX celecoxib capsules Cardiovascular Risk • CELEBREX ..., accessed July 14, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020998s026lbl.pdf
29. Study Results | Celebrex In Acute Gouty Arthritis Study | ClinicalTrials.gov, accessed July 14, 2025, https://clinicaltrials.gov/study/NCT00549549?cond=%22Arthropathy%22&intr=%22Celecoxib%22&viewType=Table&rank=3&tab=results
30. Celebrex In Acute Gouty Arthritis Study - ClinicalTrials.gov, accessed July 14, 2025, https://www.clinicaltrials.gov/study/NCT00549549
31. Efficacy and tolerability of celecoxib in the treatment of acute gouty arthritis: a randomized controlled trial - PubMed, accessed July 14, 2025, https://pubmed.ncbi.nlm.nih.gov/22859357/
32. Celecoxib Adjunctive Treatment to Antipsychotics in Schizophrenia: A Review of Randomized Clinical Add-On Trials - PubMed Central, accessed July 14, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4976163/
33. Celecoxib for Mood Disorders: A Systematic Review and Meta-Analysis of Randomized Controlled Trials - PMC, accessed July 14, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10218898/
34. Beneficial Antipsychotic Effects of Celecoxib Add-On Therapy Compared to Risperidone Alone in Schizophrenia | American Journal of Psychiatry, accessed July 14, 2025, https://psychiatryonline.org/doi/full/10.1176/appi.ajp.159.6.1029
35. Off-Label Prescribing - AACAP, accessed July 14, 2025, https://www.aacap.org/aacap/Policy_Statements/2018/Off_Label_Prescribing.aspx
36. Shoulder Pain Recruiting Phase 4 Trials for Celecoxib (DB00482) | DrugBank Online, accessed July 14, 2025, https://go.drugbank.com/indications/DBCOND0002120/clinical_trials/DB00482?phase=4&status=recruiting
37. Open Label Study to Evaluate Ciprofloxacin/Celecoxib Combination in Patients With ALS, accessed July 14, 2025, https://clinicaltrials.gov/study/NCT04165850?cond=%22Lateral%20Sclerosis%22&intr=%22anti-inflammatory%20agents,%20non-steroidal%22&viewType=Table&rank=5
38. CELEBREX® (celecoxib) capsules, for oral use - This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda, accessed July 14, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020998s054lbl.pdf
39. Celecoxib | Side Effects, Dosage, Uses, and More - Healthline, accessed July 14, 2025, https://www.healthline.com/health/celecoxib-oral-capsule
40. www.medicalnewstoday.com, accessed July 14, 2025, https://www.medicalnewstoday.com/articles/celebrex#:~:text=for%20cardiovascular%20problems.-,A%20boxed%20warning%20is%20the%20most%20serious%20warning%20from%20the,as%20heart%20attack%20or%20stroke.
41. N20998S021 Celecoxib Clinical BPCA - FDA, accessed July 14, 2025, https://www.fda.gov/files/drugs/published/N20998S021-Celecoxib-Clinical-BPCA.pdf
42. CDER Statement: FDA Approves Labeling Supplement for Celebrex ..., accessed July 14, 2025, https://www.fda.gov/drugs/drug-safety-and-availability/cder-statement-fda-approves-labeling-supplement-celebrex-celecoxib
43. Ask the Doctors - Which over-the-counter pain reliever is best? - UCLA Health, accessed July 14, 2025, https://www.uclahealth.org/news/article/ask-the-doctors-which-over-the-counter-pain-reliever-is-best
44. www.goodrx.com, accessed July 14, 2025, https://www.goodrx.com/classes/nsaids/is-celebrex-better-than-ibuprofen#:~:text=Celebrex%20(celecoxib)%20is%20an%20NSAID,OTC)%20and%20as%20a%20prescription.%2520and%2520as%2520a%2520prescription.&sa=D&source=editors&ust=1752476544726410&usg=AOvVaw2pdQSrWxbu367JTfcv5sKy)
45. Celebrex vs. Naproxen for Rheumatoid Arthritis and Osteoarthritis - GoodRx, accessed July 14, 2025, https://www.goodrx.com/compare/celebrex-vs-naproxen
46. Review of the selective COX-2 inhibitors celecoxib and rofecoxib: focus on clinical aspects - Canadian Association of Emergency Physicians, accessed July 14, 2025, https://caep.ca/periodicals/Volume_4_Issue_4/Vol_4_Issue_4_Page_268_-_275_Loewen.pdf
47. Celecoxib: Package Insert / Prescribing Information - Drugs.com, accessed July 14, 2025, https://www.drugs.com/pro/celecoxib.html
48. Celecoxib oral capsule interactions: Alcohol, medications, and other factors, accessed July 14, 2025, https://www.medicalnewstoday.com/articles/drugs-celecoxib-capsule-interactions
49. www.ncbi.nlm.nih.gov, accessed July 14, 2025, https://www.ncbi.nlm.nih.gov/books/NBK535359/#:~:text=Celecoxib%20is%20a%20generally%20safe,elevated%20AST%2FALT%20or%20BUN.
50. Is meloxicam very similar to Celebrex? - Drugs.com, accessed July 14, 2025, https://www.drugs.com/medical-answers/is-meloxicam-very-similar-to-celebrex-84849/
51. Celecoxib Interactions Checker - Drugs.com, accessed July 14, 2025, https://www.drugs.com/drug-interactions/celecoxib.html
52. Celecoxib and Interactions: Other Drugs, Supplements, and More - Healthline, accessed July 14, 2025, https://www.healthline.com/health/drugs/celecoxib-interactions
53. Celebrex Vs Ibuprofen | Power - Clinical Trials, accessed July 14, 2025, https://www.withpower.com/guides/celebrex-vs-ibuprofen
54. Celebrex vs. naproxen: Differences, similarities, and which is better ..., accessed July 14, 2025, https://www.singlecare.com/blog/celebrex-vs-naproxen/
55. Celebrex vs. ibuprofen: Differences, similarities, and which is better ..., accessed July 14, 2025, https://www.singlecare.com/blog/celebrex-vs-ibuprofen/
56. Ibuprofen vs. Celebrex for Rheumatoid Arthritis and Osteoarthritis: Important Differences and Potential Risks. - GoodRx, accessed July 14, 2025, https://www.goodrx.com/compare/ibuprofen-vs-celebrex
57. Seglentis (celecoxib and tramadol hydrochloride) FDA Approval History - Drugs.com, accessed July 14, 2025, https://www.drugs.com/history/seglentis.html
58. www.goodrx.com, accessed July 14, 2025, https://www.goodrx.com/celecoxib/what-is#:~:text=Yes%2C%20celecoxib%20is%20the%20lower,prescription%20from%20your%20provider%20only.
59. Celebrex Medicare Coverage and Co-Pay Details - GoodRx, accessed July 14, 2025, https://www.goodrx.com/celebrex/medicare-coverage
60. Celebrex vs. Ibuprofen: Which Is Better? - GoodRx, accessed July 14, 2025, https://www.goodrx.com/classes/nsaids/is-celebrex-better-than-ibuprofen